Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
For decades, the standard of care for diabetic kidney disease has centered on blood pressure control, glycemic management, and renin-angiotensin system (RAS) blockade with ACE inhibitors or ARBs. SGLT2 inhibitors emerged in the 2010s as a major addition to this toolkit. In May 2024, the New England Journal of Medicine published results from FLOW, the trial that established semaglutide as the first GLP-1 receptor agonist with definitive kidney outcome benefit in patients with type 2 diabetes and CKD.
Why GLP-1 Agonists for Kidney Disease?
GLP-1 receptors are expressed not only in the pancreas and brain, but in the kidney — particularly in the renal vasculature, glomeruli, and tubular cells. Mechanistic research over the past decade suggested that GLP-1 receptor agonism could produce renoprotective effects through multiple pathways: reduced inflammation, improved endothelial function, modulation of the renin-angiotensin system, and indirect benefits via weight loss, blood pressure reduction, and better glycemic control. Early signals from the cardiovascular outcome trials (LEADER, SUSTAIN-6, REWIND) suggested kidney benefits, but these trials were not designed primarily to test kidney endpoints. FLOW was.
The FLOW Trial Design
FLOW (Effect of Semaglutide vs. Placebo on Kidney Outcomes in People with Type 2 Diabetes and Chronic Kidney Disease) was a Phase 3, double-blind, placebo-controlled trial that randomized 3,533 adults with type 2 diabetes plus established CKD (defined by reduced eGFR or significant albuminuria) to weekly subcutaneous semaglutide 1.0 mg or placebo. Median follow-up was 3.4 years. The trial was stopped early at a prespecified interim analysis because of clear efficacy.
The primary outcome was a composite of major kidney disease events: kidney failure (initiation of chronic kidney replacement therapy or sustained eGFR <15), persistent ≥50% reduction in eGFR, kidney-related death, or cardiovascular death.
Primary Outcome
The risk of a primary-outcome event was 24% lower in the semaglutide group than in the placebo group (331 vs. 410 first events; hazard ratio 0.76, 95% CI 0.66-0.88; P=0.0003). The benefit was consistent across pre-specified subgroups including baseline eGFR, albuminuria category, and concurrent SGLT2 inhibitor use.
Key Secondary Outcomes
The mean annual eGFR slope was less steep — indicating a slower decline in kidney function — by 1.16 mL/min/1.73 m² per year in the semaglutide group versus placebo (P<0.001). Over years, this difference compounds to substantial preservation of remaining kidney function.
The risk of major cardiovascular events (MACE) was 18% lower in the semaglutide group (hazard ratio 0.82). This is consistent with the established cardiovascular benefit of GLP-1 receptor agonists demonstrated in prior trials.
The risk of death from any cause was 20% lower with semaglutide than with placebo. This is a substantial mortality reduction in a chronic disease population.
There were fewer serious adverse events in the semaglutide group than in the placebo group (49.6% vs. 53.8%) — meaning the active treatment was actually safer than placebo overall when considering composite adverse events. This is unusual and reflects the disease-modifying nature of the therapy.
Clinical Implications
FLOW transforms the clinical landscape for patients with type 2 diabetes and CKD. Implications include:
- Indication expansion. Semaglutide now has evidence-based use beyond glycemic control and weight management — into nephroprotection.
- Combination therapy. SGLT2 inhibitors and GLP-1 agonists show benefits through different mechanisms; combination use is increasingly recommended in kidney guidelines.
- Earlier intervention. The benefit was observed across CKD stages 2-4, suggesting GLP-1 RAs may slow disease progression even in earlier kidney disease.
- Mortality benefit. A 20% reduction in all-cause mortality is rare for any single therapy and underscores the multi-system nature of GLP-1 RA effects.
Important Caveats
FLOW was conducted in patients with type 2 diabetes; it does not directly apply to patients with non-diabetic CKD. Semaglutide should be initiated by a clinician familiar with kidney disease management — including monitoring of eGFR, GLP-1-related adverse effects, and interactions with other medications. Patients on dialysis were excluded from FLOW; whether semaglutide benefits this population is the subject of ongoing research.
What This Means at Irvine Health
For patients with both type 2 diabetes and chronic kidney disease considering peptide therapy, FLOW provides a strong evidence base for semaglutide that extends beyond glycemic and weight management. As always, our physicians evaluate individual circumstances — including current kidney function, concurrent medications, and overall health goals — when designing any protocol. The FLOW data add a substantial layer of evidence that, in carefully selected patients, semaglutide may offer benefits well beyond what was documented in the original obesity and diabetes trials.
References
- Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. DOI: 10.1056/NEJMoa2403347.
- Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD). N Engl J Med. 2020;383:2219-2229.
- Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436-1446.
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
- American Diabetes Association. Standards of Medical Care in Diabetes (2024).